Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study
| العنوان: | Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study |
|---|---|
| المؤلفون: | Ivona Žužul, Vanja Vučićević-Boras, Vlaho Brailo, Ana Andabak Rogulj, Ivan Alajbeg, Ivana Škrinjar, Iva Alajbeg |
| المصدر: | PLoS ONE, Vol 16, Iss 4, p e0249862 (2021) PLoS ONE |
| بيانات النشر: | Public Library of Science (PLoS), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, NAVS naphthalan, oral lichen planus, recurrent aphthous stomatitis, Administration, Topical, Anti-Inflammatory Agents, Betamethasone dipropionate, Biochemistry, Betamethasone, Gastroenterology, Steroid Therapy, Medical Conditions, Oral Diseases, Quality of life, Medicine and Health Sciences, Materials, Multidisciplinary, Organic Compounds, Pharmaceutics, Middle Aged, Lipids, Chemistry, Physical Sciences, Medicine, Steroids, Female, Stomatitis, Aphthous, medicine.symptom, Research Article, medicine.drug, medicine.medical_specialty, Corticosteroid Therapy, Science, Oral Medicine, Materials Science, Pain, Naphthalenes, Lesion Number, Recurrent aphthous stomatitis, Lesion, Signs and Symptoms, Drug Therapy, Adhesives, Internal medicine, medicine, Humans, Aged, business.industry, Organic Chemistry, Chemical Compounds, Biology and Life Sciences, medicine.disease, Naphthalan, Health Care, stomatognathic diseases, Lesions, Quality of Life, Oral lichen planus, Clinical Medicine, business, Oils, Lichen Planus, Oral |
| الوصف: | Aim To evaluate the effectiveness of non-aromatic very rich in steranes (NAVS) naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Null hypothesis was that there would be no difference between NAVS and topical steroids in the treatment of OLP and RAS. Methods The study consisted of two sub-trials conducted as randomized, double-blind controlled studies: first included OLP patients and second patients with RAS. Patients received either NAVS or 0.05% betamethasone dipropionate. Primary outcomes were activity score (OLP patients), No of lesions and lesion diameter (RAS patients) and pain intensity (VAS) while secondary outcome included the impact of the disease on quality of life assessed by Oral health impact profile (OHIP 14). Results No significant differences in terms of OLP clinical signs (p = 0.84, η2 = 0.001) and responses on the OHIP-14 (p = 0.81, η2 = 0.002) or on VAS (p = 0.14, η2 = 0.079) between NAVS and betamethasone groups were observed. In RAS patients, no significant differences between the groups in terms of lesion number (at days 3 and 5, p = 0.33 and p = 0.98, respectively), lesion diameter (days 3 and 5, p = 0.24 and p = 0.84, respectively) were observed. However, in NAVS group a significant reduction of lesions diameter was observed on the 3rd day, while in betamethasone group a significant reduction in lesions diameter was evident only after the 5th day. No significant differences in VAS (p > 0.05) and the OHIP-14 (p > 0.05) between groups were found. Conclusion No evidence of differences between the two compared interventions was found. Registration Retrospective registration of this trial was conducted in ClinicalTrials.gov on September 30, 2016; trial registration number: NCT02920658. https://clinicaltrials.gov/ct2/show/NCT02920658?term=NAVS&draw=2&rank=4Test. |
| اللغة: | English |
| تدمد: | 1932-6203 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e48adc1b226c1e4357e739d3d13e169Test https://doaj.org/article/ac12ca3b01d24455a1c232842b9d44a2Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6e48adc1b226c1e4357e739d3d13e169 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|